<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04166331</url>
  </required_header>
  <id_info>
    <org_study_id>87RI18_0012 (ADAPT)</org_study_id>
    <nct_id>NCT04166331</nct_id>
  </id_info>
  <brief_title>Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion</brief_title>
  <acronym>ADAPT</acronym>
  <official_title>Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion: a Randomized Controlled Multi-center Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre d'Investigation Clinique 1415</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis induces both a systolic and diastolic cardiac dysfunction. The prevalence of this&#xD;
      septic cardiomyopathy ranges between 30 and 60% according to the timing of assessment and&#xD;
      definition used. Although the prognostic role of septic cardiomyopathy remains debated,&#xD;
      sepsis-induced left ventricular (LV) systolic dysfunction may be severe and associated with&#xD;
      tissue hypoperfusion, while it appears to fully recover in survivors. Accordingly,&#xD;
      optimization of therapeutic management of septic cardiomyopathy may contribute to improve&#xD;
      tissue hypoperfusion in increasing oxygen delivery, and to reduce related organ dysfunctions&#xD;
      in septic shock patients.&#xD;
&#xD;
      Echocardiography is currently the recommended first-line modality to assess patients with&#xD;
      acute circulatory failure.&#xD;
&#xD;
      Current Surviving Sepsis Campaign strongly recommends Norepinephrine as the first-choice&#xD;
      vasopressor in fluid-filled patients with septic shock. In contrast, the use of Dobutamine is&#xD;
      only suggested (weak recommendation, low quality of evidence) in patients with persistent&#xD;
      tissue hypoperfusion despite adequate fluid resuscitation and vasopressor support.&#xD;
      Levosimendan, an alternative inodilator, has failed preventing acute organ dysfunction in&#xD;
      septic patients and has induced more supraventricular tachyarrhythmias than in the control&#xD;
      group. Data supporting Dobutamine in this setting are scarce and primarily physiologic and&#xD;
      based on monitored effects of this drug on hemodynamics and indices of tissue perfusion.&#xD;
&#xD;
      No randomized controlled trials have yet compared the effects of Dobutamine versus placebo on&#xD;
      clinical outcomes. In open-labelled, small sample trials, the ability of septic patients to&#xD;
      increase their oxygen delivery during Dobutamine administration appears to be associated with&#xD;
      lower mortality.&#xD;
&#xD;
      The tested hypothesis in the ADAPT trial is that Dobutamine will reduce tissue hypoperfusion&#xD;
      and associated organ dysfunctions in patients with septic shock and associated septic&#xD;
      cardiomyopathy. In doing so, it may participate in improving clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2020</start_date>
  <completion_date type="Anticipated">September 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) score evolution</measure>
    <time_frame>Day 0 to Day 3</time_frame>
    <description>Evolution of a modified Sequential (Sepsis-Related) Organ Failure Assessment (SOFA) score (no gradation of the neurologic system) between baseline (before randomization) and Day 1, Day 2 and Day 3 after randomization. Min value =0. Max value =20 . The highest score means the worst situation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circulating lactate level measurement</measure>
    <time_frame>Hour 0, Hour 6, Day 1, Day 2 and Day 3</time_frame>
    <description>Biological indices of tissue dysoxia at baseline, hour 6, Day1, Day 2 and Day 3 after initiating Dobutamine / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central venous oxygen saturation (ScvO2) measurement</measure>
    <time_frame>Hour 0, Hour 6, Day 1, Day 2 and Day 3</time_frame>
    <description>Biological indices of tissue dysoxia at baseline, hour 6, Day1, Day 2 and Day 3 after initiating Dobutamine / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Open-labelled Dobutamine dayly maximal dose used as rescue therapy</measure>
    <time_frame>through study completion, an average 90 days</time_frame>
    <description>Requirement of organ function supports during ICU stay. Maximal dose in mcg/kg/min of open-labelled Dobutamine used as rescue therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Open-labelled Dobutamine duration used as rescue therapy</measure>
    <time_frame>through study completion, an average of 90 days</time_frame>
    <description>Requirement of organ function supports during ICU stay. Duration in days of open-labelled Dobutamine used as rescue therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor support duration</measure>
    <time_frame>through study completion, an average of 90 days</time_frame>
    <description>Requirement of organ function supports during ICU stay. Duration in days of vasopressor support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor support dayly maximal dose</measure>
    <time_frame>through study completion, an average of 90 days</time_frame>
    <description>Requirement of organ function supports during ICU stay. Maximal dose in mg/h by day of vasopressor support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive mechanical ventilation duration</measure>
    <time_frame>through study completion, an average of 90 days</time_frame>
    <description>Requirement of organ function supports during ICU stay. Duration of invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy number</measure>
    <time_frame>through study completion, an average of 90 days</time_frame>
    <description>Requirement of organ function supports during ICU stay. Number of session of renal replacement therapy (excluding hemodialysis patient for chronic renal failure at the time of randomization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy duration</measure>
    <time_frame>through study completion, an average of 90 days</time_frame>
    <description>Requirement of organ function supports during ICU stay. Duration of renal replacement therapy (excluding hemodialysis patient for chronic renal failure at the time of randomization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial pressure measurement</measure>
    <time_frame>Hour 0, Hour 6, Day 1, Day 2 and Day 3</time_frame>
    <description>Systolic, diastolic and mean arterial blood pressure (in mmHg) at Baseline, h6, Day 1, Day 2 and Day3after initiating Dobutamine / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate measurement</measure>
    <time_frame>Hour 0, Hour 6, Day 1, Day 2 and Day 3</time_frame>
    <description>Heart rate measurement in bpm at Baseline, Hour 6, Day 1, Day 2 and Day3 after initiating Dobutamine / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central venous pressure measurement</measure>
    <time_frame>Hour 0, Hour 6, Day 1, Day 2 and Day 3</time_frame>
    <description>Central venous pressure in cm H2O at Baseline, Hour 6, Day 1, Day 2 and Day3 after initiating Dobutamine / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac index measurement</measure>
    <time_frame>Hour 0, Hour 6, Day 1, Day 2 and Day 3</time_frame>
    <description>Cardiac index measurement in L/min/m2 at Baseline, Hour 6, Day 1, Day 2 and Day3 after initiating Dobutamine / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke volume measurement</measure>
    <time_frame>Hour 0, Hour 6, Day 1, Day 2 and Day 3</time_frame>
    <description>Stroke volume measurement in mL status at Baseline, Hour 6, Day 1, Day 2 and Day3 after initiating Dobutamine / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypotension measurement</measure>
    <time_frame>Hour 0, Hour 6, Day 1, Day 2 and Day 3</time_frame>
    <description>Severe cardiovascular adverse events from inform consent to ICU discharge : Hypotension related to worsened vasoplegia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supraventricular arrhythmias measurement</measure>
    <time_frame>through study completion, an average of 90 days</time_frame>
    <description>Severe cardiovascular adverse events from inform consent to ICU discharge. Supraventricular arrhythmias with ventricular rate &gt; 140 bpm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular arrhythmias measurement</measure>
    <time_frame>through study completion, an average of 90 days</time_frame>
    <description>Severe cardiovascular adverse events from inform consent to ICU discharge. Ventricular arrhythmias</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of Acute coronary syndrome</measure>
    <time_frame>through study completion, an average of 90 days</time_frame>
    <description>Severe cardiovascular adverse events from inform consent to ICU discharge. Acute coronary syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of Stroke</measure>
    <time_frame>through study completion, an average of 90 days</time_frame>
    <description>Severe cardiovascular adverse events during ICU stay. Stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 90</time_frame>
    <description>Number of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality causes</measure>
    <time_frame>Day 90</time_frame>
    <description>Cause of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ function free supports</measure>
    <time_frame>Day 90</time_frame>
    <description>Number of days free from vasopressor support, invasive mechanical ventilation, renal replacement therapy from inform consent to ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in ICU and hospital</measure>
    <time_frame>Day 90</time_frame>
    <description>Length of ICU and hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>echocardiographic assessment of left ventricular systolic function</measure>
    <time_frame>Day 0 and Day 1</time_frame>
    <description>ejection fraction measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leucocyte subsets level</measure>
    <time_frame>Hour 6</time_frame>
    <description>Leucocyte subsets level according to the severity of the sepsis-induced LV systolic dysfunction and hemodynamic effects of the study drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines level</measure>
    <time_frame>Hour 6</time_frame>
    <description>tumor necrosis factor (TNF) -α, Interferon ɣ, Interleukin-6, 8 and 10 cytokines concentration will be assess according to the severity of the sepsis-induced LV systolic dysfunction and hemodynamic effects of the study drug administration. Result for each cytokine concentration will be given in picograms per milliliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV global longitudinal strain measurement</measure>
    <time_frame>Hour 6, Day 1, Day 2 AND Day 3</time_frame>
    <description>LV segmental deformation longitudinal analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RV free wall strain measurement</measure>
    <time_frame>Hour 6, Day 1, Day 2 AND Day 3</time_frame>
    <description>deformation of right ventricular myocardial tissue / routinely using with echocardiography or post exam analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV volume measurement</measure>
    <time_frame>Hour 6, Day 1, Day 2 AND Day 3</time_frame>
    <description>Ratio between systolic and diastolic left ventricular volume / routinely using with echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV ejection fraction measurement</measure>
    <time_frame>Hour 6, Day 1, Day 2 AND Day 3</time_frame>
    <description>Cardiac output measurement with echocardiography Doppler (in centers routinely using transpulmonary thermodilution). Quality of left ventricular contraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RV volume measurement</measure>
    <time_frame>Hour 6, Day 1, Day 2 AND Day 3</time_frame>
    <description>Ratio between systolic and diastolic right ventricular volume / routinely using with echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RV ejection fraction measurement</measure>
    <time_frame>Hour 6, Day 1, Day 2 AND Day 3</time_frame>
    <description>Cardiac output measurement with echocardiography Doppler (in centers routinely using transpulmonary thermodilution). Quality of right ventricular contraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transpulmonary thermodilution measurement</measure>
    <time_frame>Hour 6, Day 1, Day 2 AND Day 3</time_frame>
    <description>In selected centers routinely using continuous monitoring of cardiac output using transpulmonary thermodilution: agreement of cardiac output measurement with echocardiography Doppler.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Sepsis</condition>
  <condition>Cardiomyopathies</condition>
  <condition>Hypoperfusion</condition>
  <condition>Left Ventricular Systolic Dysfunction</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dobutamine will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min. Dose adaptation will be left at the discretion of attending physician.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dobutamine</intervention_name>
    <description>Dobutamine will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min. Dose adaptation will be left at the discretion of attending physician.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years hospitalized in ICU&#xD;
&#xD;
          -  &gt; Septic shock (Sepsis-3 definition):&#xD;
&#xD;
               1. Clinically suspected or documented acute infection&#xD;
&#xD;
               2. Responsible for organ dysfunction(s): change in SOFA ≥ 2 points&#xD;
&#xD;
               3. With persisting hypotension (systolic and/or mean arterial pressure &lt; 90 / &lt; 65&#xD;
                  mmHg) despite adequate fluid resuscitation (≥ 30 mL/kg, unless presence of&#xD;
                  pulmonary venous congestion)&#xD;
&#xD;
               4. Requiring vasopressor support (Norepinephrine) to maintain steady mean arterial&#xD;
                  pressure ≥ 65 mmHg&#xD;
&#xD;
               5. And lactate &gt; 2 mmol/L&#xD;
&#xD;
          -  Septic cardiomyopathy: echocardiographically measured LV ejection fraction (EF) ≤ 40%&#xD;
             and LV outflow tract velocity-time integral &lt; 14 cm&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Hypersensitivity to Dobutamine, 5% Dextrose, or to the excipients&#xD;
&#xD;
          -  Ventricular rate &gt; 130 bpm (sinus rhythm or not)&#xD;
&#xD;
          -  Severe ventricular arrhythmia&#xD;
&#xD;
          -  Obstructive cardiomyopathy with pressure gradient at rest ≥ 50 mmHg unrelated to&#xD;
             uncorrected hypovolemia&#xD;
&#xD;
          -  Severe aortic stenosis: mean gradient &gt; 40 mmHg, peak aortic jet velocity &gt; 4 m/s,&#xD;
             aortic valve area &lt; 1 cm² (aortic valve area index &lt; 0.6 cm²/m²)&#xD;
&#xD;
          -  Acute coronary syndrome&#xD;
&#xD;
          -  Decision to limit care or moribund status (life expectancy &lt; 24 h)&#xD;
&#xD;
          -  Absence of affiliation to Social Security&#xD;
&#xD;
          -  Subjects under juridical protection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>VIGNON Philippe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>VIGNON Philippe, MD</last_name>
    <phone>555054040</phone>
    <phone_ext>+33</phone_ext>
    <email>philippe.vignon@chu-limoges.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>BOURZEIX Paul</last_name>
    <email>paul.bourzeix@chu-limoges.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel SLAMA, MD</last_name>
      <phone>+33322455854</phone>
      <email>slama.michel@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Michel SLAMA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien MAIZEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loay KONTAR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Angouleme Hospital</name>
      <address>
        <city>Angoulême</city>
        <zip>16959</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane ROULEAU, MD</last_name>
      <phone>545244157</phone>
      <phone_ext>+33</phone_ext>
      <email>stephane.rouleau@ch-angouleme.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane ROULEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Argenteuil Hospital</name>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaëtan PLANTEFEVE, MD</last_name>
      <phone>134232550</phone>
      <email>gaetan.plantefeve@ch-argenteuil.fr</email>
    </contact>
    <investigator>
      <last_name>Gaëtan PLANTEFEVE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwanaël PRAT, MD</last_name>
      <phone>+33298347181</phone>
      <email>gwenael.prat@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Gwanaël PRAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre BAILLY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aphp - Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MEKONTSO-DESSAP Armand, MD</last_name>
    </contact>
    <investigator>
      <last_name>MEKONTSO-DESSAP Armand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dijon university hospital</name>
      <address>
        <city>Dijon</city>
        <zip>21033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre QUENOT, MD</last_name>
      <phone>380295921</phone>
      <phone_ext>+33</phone_ext>
      <email>jean-pierre.quenot@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre QUENOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Limoges University Hospital</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Vignon, MD</last_name>
      <phone>+33555054040</phone>
      <email>philippe.vignon@chu-limoges.fr</email>
    </contact>
    <contact_backup>
      <last_name>Fanny MAMERT</last_name>
      <phone>555056562</phone>
      <phone_ext>+33</phone_ext>
      <email>fanny.mamert@chu-limoges.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Philippe Vignon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno François, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Daix, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno LEVY, MD</last_name>
      <phone>383154084</phone>
      <phone_ext>+33</phone_ext>
      <email>b.levy@chru-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno LEVY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas AUCHER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline FRITZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine KIMMOUN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon LEMOINE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathieu MATTEI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre PEREZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carine THIVILLIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christelle SIMONOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Orléans - service de Réanimation</name>
      <address>
        <city>Orleans</city>
        <zip>47067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry BOULAIN, MD</last_name>
      <phone>02 38 51 44 46</phone>
      <email>thierry.boulain@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Boulain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Armelle Mathonnet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dalila Benzekri-Lefèvre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Bretagnol, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle Rugne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François Barbier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grégoire Muller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Toufik Kamel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mai-Anh Nay, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aphp - Ambroise Paré</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine VIEILLARD-BARON, MD</last_name>
      <phone>+33149095603</phone>
      <email>antoine.vieillard-baron@apr.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine VIEILLARD-BARON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier REPESSE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cyril CHARRON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin - service de Réanimation</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Paul MIRA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Paul MIRA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poitiers University Hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence BOISSIER, MD</last_name>
      <phone>549444367</phone>
      <phone_ext>+33</phone_ext>
      <email>florence.boissier@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Florence BOISSIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg - service de Réanimation</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferhat MEZIANI, MD</last_name>
      <phone>03 69 55 04 34</phone>
      <email>ferhat.meziani@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Ferhat Meziani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Kummerlen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tarik Khoury, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier Delabranche, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hassene Rahmani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Heenen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yannick Rabouel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra Boivin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra Monnier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie Boisramé-Helms, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tours - Service de Réanimation</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle MERCIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre-François Dequin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Youenn Jouan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine Guillon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Garot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle Mercier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stepahn Ehrmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laetitia Bodet-Contentin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle Rouve, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie Mankikian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annick Legras, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte Salmon-Gandonnière, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>Cardiomyopathies</keyword>
  <keyword>Hypoperfusion</keyword>
  <keyword>Left Ventricular Systolic Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
    <mesh_term>Systolic Murmurs</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dobutamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

